A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis-Reference-Cited by-同舟云学术

A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis

Published:2022-10 Issue: Volume:66 Page:104059
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Mathew Thomas^ORCID,Kamath Vikram,John Saji K,Netravathi M,Iyer Rajesh B,Raghavendra S,Kumar Suresh,Neeharika M.L.,Gupta Salil,Murgod Uday,Shivakumar R.,Annadure Ravi K,Ichaporia Nasli,Rohatgi Anshu,Nair Sruthi S,Yareeda Sireesha,Anand Bawani,Singh Prabhjeet,Renukaradhya Umashankar,Arulselvan V.,Reddy Y Muralidhar,Surya Nirmal,Sarma G.R.K.,Nadig Raghunandan,Deepalam Saikanth,Sharath Kumar G.G.,Satishchandra P.,Singhal Bhim Sen,Parry Gareth

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference18 articles.

1. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Alping;Ann. Neurol.,2016

2. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis;Brown;JAMA,2019

3. Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP);Butzkueven;J. Neurol. Neurosurg. Psychiatry,2020

4. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases;Clifford;Lancet Neurol.,2010

5. α4-integrin receptor desaturation and disease activity return after natalizumab cessation;Derfuss;Neurol. Neuroimmunol. Neuroinflamm.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

2. Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches;Immunopharmacology and Immunotoxicology;2024-04-18